270 related articles for article (PubMed ID: 23540512)
1. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids.
Mercadante S; Porzio G; Aielli F; Adile C; Verna L; Ficorella C; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):661-6. PubMed ID: 23540512
[TBL] [Abstract][Full Text] [Related]
2. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.
Mercadante S; Porzio G; Adile C; Aielli F; Cortegiani A; Dickenson A; Casuccio A
Curr Med Res Opin; 2014 Oct; 30(10):2063-8. PubMed ID: 24926734
[TBL] [Abstract][Full Text] [Related]
3. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
4. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
6. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
[TBL] [Abstract][Full Text] [Related]
7. [Sustained-release Opioids: Morphine, Oxycodone and Tapentadol].
Takahashi Y; Iseki M
Masui; 2015 Nov; 64(11):1133-40. PubMed ID: 26689063
[TBL] [Abstract][Full Text] [Related]
8. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
Christoph T; De Vry J; Tzschentke TM
Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
[TBL] [Abstract][Full Text] [Related]
9. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
10. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review.
Mercadante S
Curr Med Res Opin; 2017 Nov; 33(11):1965-1969. PubMed ID: 28906155
[TBL] [Abstract][Full Text] [Related]
11. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs.
Kögel B; Terlinden R; Schneider J
Vet Anaesth Analg; 2014 May; 41(3):297-304. PubMed ID: 24576316
[TBL] [Abstract][Full Text] [Related]
13. Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit.
Mercadante S
Pain Med; 2012 Mar; 13(3):399-404. PubMed ID: 22360828
[TBL] [Abstract][Full Text] [Related]
14. Tapentadol extended release for chronic pain patients.
Taylor R; Pergolizzi JV; Raffa RB
Adv Ther; 2013 Jan; 30(1):14-27. PubMed ID: 23328938
[TBL] [Abstract][Full Text] [Related]
15. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
17. Rapid switching between transdermal fentanyl and methadone in cancer patients.
Mercadante S; Ferrera P; Villari P; Casuccio A
J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
[TBL] [Abstract][Full Text] [Related]
18. Tapentadol. Acute or chronic pain: no therapeutic advance.
Prescrire Int; 2014 May; 23(149):121-4. PubMed ID: 24926510
[TBL] [Abstract][Full Text] [Related]
19. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
20. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
